Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01187836 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure
A Phase 1 study, sponsored by Trevena.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01187836 is a Phase 1 study that has completed, run by Trevena. The registered enrollment target is 33 participants.
The verdict
NCT01187836, a Phase 1 study, has completed, sponsored by Trevena.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
In this study, TRV120027 (or a placebo) intravenous infusion will be given to people with heart failure to learn about the effects of TRV120027. The results of this study will help choose the proper range of TRV120027 doses to use in future research studies involving patients with acute decompensated heart failure.
Interventions
- DRUG Placebo
- DRUG TRV120027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01187836
The ClinicalTrials.gov registry entry for NCT01187836 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trevena, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01187836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01187836 about?
NCT01187836 is a clinical study titled "Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure". In this study, TRV120027 (or a placebo) intravenous infusion will be given to people with heart failure to learn about the effects of TRV120027. The results of this study will help choose the proper range of TRV120027 doses to use in future research studies involving patients with acute decompensate...
What is the current status of trial NCT01187836?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2010-12. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01187836?
The interventions under investigation include: Placebo (DRUG), TRV120027 (DRUG).
Who is sponsoring clinical trial NCT01187836?
This trial is sponsored by Trevena, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.